retatrutide eli lilly press release 2024 2025 touts strong results of new experimental weight loss drug Eli Lilly's weight loss drug

Weight loss was sustained over 4 years [127]

Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review

GLP-1 enhances proliferation and inhibits apoptosis of pancreatic beta cells with beneficial effects on beta cell mass

Changed Food Preferences Perhaps most fascinating is how these medications appear to alter food preferences: Decreased desire for ultra-processed foods and sugary treats Increased enjoyment of whole, nutrient-dense foods Reduced interest in alcohol consumption One study participant noted: "I used to crave fast food daily

Its typically most pronounced at the beginning of treatment and sometimes when dosage is increased

Clinical trial data do not apply: Eli Lilly's investigational Retatrutide has been studied in human clinical trials, and adverse event data from those trials are published [3]